March 14th 2023
This subtype of artificial intelligence technology may have long-range implications for clinical trials.
February 22nd 2023
Glaucoma 360: Home tonometry - worth the pressure?February 4th 2023
Robert L. Stamper, MD, discusses some of the devices in development for measuring patients' intraocular pressure outside of doctors' office hours in his presentation at Glaucoma Research Foundation's annual Glaucoma Symposium.
Glaucoma 360: An update on IOLs - when and how to use themFebruary 4th 2023
Shan C. Lin, MD, provides an overview of the various intraocular lens technologies that are available, as well as considerations for contrast sensitivity and vision loss in patients at Glaucoma Research Foundation's annual Glaucoma Symposium.
Glaucoma 360: A bird's-eye view of innovationFebruary 3rd 2023
Kristen H. Ingenito, MBA, vice president and director of ophthalmics at Market Scope, discusses the volume of ophthalmologists offering interventional glaucoma treatment as well as emerging therapies in her presentation at the Glaucoma 360 New Horizons Forum.
Poll: How familiar are you on the approval process for biosimilar drugs in comparison to new drug applications to the FDA?January 27th 2023
Let us know how familiar are you on the approval process for biosimilar drugs compared with new drug applications to the FDA. The poll will be open until February 28, 2023.
Innovation Pharmaceuticals details in vivo antifungal data showing brilacidin’s potential for treating fungal keratitisDecember 20th 2022
Previous research conducted primarily by scientists at the University of São Paulo, Brazil, showed brilacidin can potentiate several marketed antifungals, including caspofungin, voriconazole and posaconazole.
Wilmer Eye Institute, Bascom Palmer take top honors in Ophthalmology Times' 2022 Best Programs AwardsDecember 19th 2022
Survey of academic chairs and residency directors recognizes centers of excellence in Best Clinical Care, Best Residency, Best Research, and Best Overall Programs.
EyeCon 2022: Management options for the treatment of pediatric myopiaDecember 17th 2022
Jefferson Doyle, MBBCh, MD, PhD, MHS, of the Wilmer Eye Institute at Johns Hopkins University School of Medicine, addresses myopic concerns, such as public health measures including time outdoors, as well as pharmacological approaches including the current atropine data that has been completed and ongoing studies.
EyeCon 2022: Ophthalmology Times co-chairs discuss highlights of Day 1December 17th 2022
Ophthalmology Times®' EyeCon co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute, and glaucoma specialist Oluwatosin U. Smith MD, from Glaucoma Associates of Texas, discuss some of the highlights of EyeCon 2022.
EyeCon 2022: Important updates in retinopathy of prematurity for cliniciansDecember 17th 2022
Julius Oatts, MD, covered a range of current considerations for retinopathy of prematurity (ROP), including the updated International Classification for ROP, clinical research, and some of the socioeconomic factors that affect ROP. Oatts is assistant professor and associate residency program director with the Department of Ophthalmology at the University of California, San Francisco.
BRIM Biotechnology receives FDA orphan drug designation for treatment of neurotrophic keratitisDecember 8th 2022
Receiving FDA orphan drug designation allows the company to proceed with plans to advance the development of BRM424, a novel, first-in-class, potential treatment for neurotrophic keratitis.
Ocuphire Pharma submits New Drug Application to FDA for Nyxol eye drops for reversal of mydriasisDecember 6th 2022
According to the company, the NDA is supported by positive phase data demonstrating the rapid reversal of dilated eyes and favorable safety profile in pediatric and adult subjects.
Azura Ophthalmics reveals positive results from phase 2b clinical trial of AZR-MD-001 for meibomian gland dysfunctionNovember 17th 2022
AZR-MD-001 0.5% meets co-primary efficacy endpoints, making it the first investigational drug to show significant improvements in both signs and symptoms of MGD.
Boarding Orbis Flying Eye Hospital: Not your typical flight experienceNovember 16th 2022
When it is not on a mission, the Orbis Flying Eye Hospital MD-10 aircraft often is situated at an airport where the fully accredited teaching facility is put to use as a mobile simulation center to train ophthalmologists from around the world in some of the latest sight-saving techniques.